• Alnylam's RNAi therapeutic Oxlumo gets EU green light pharmatimes
    November 23, 2020
    Alnylam Pharmaceuticals has scored an approval from the European Commission for its RNAi therapeutic Oxlumo, for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
PharmaSources Customer Service